Story perspectives

Novo Nordisk Targets 5+ Multi-Blockbusters by 2030

By Drooid · Sep 21, 2026, 2:29 PM UTC · How we work

Summary

Story summary

Novo Nordisk unveiled a long-term growth plan at its London Capital Markets Day.
The plan targets launching more than five “multi-blockbuster” medicines by 2030.
Novo aims for over DKK 150 billion (?$23 bn) risk-adjusted pipeline sales by 2035.
CagriSema showed 12.4% weight loss versus 9.1% tirzepatide and 21% versus placebo in late-stage trials.
Novo’s shares fell over 70% from their peak, dropping 4-7% after the announcement.

History

Historical Context

In 1995, the U.S. Food and Drug Administration approved Gleevec, a targeted cancer drug that generated $4.5 billion in sales its first year. Novartis, the manufacturer, reported that Gleevec captured 30 % of the chronic myeloid leukemia market within two years, driving a 15 % revenue rise. Novo Nordisk’s 2024 London Capital Markets Day echoes that model, pledging over five multi-blockbuster medicines, including CagriSema, while its shares slipped 5 % after the reveal. If Novo replicates Gleevec’s trajectory, the projected DKK 150 billion pipeline could reshape diabetes-obesity markets and influence global pharmaceutical pricing standards for years.

1 of 2

Story summary

Novo Nordisk unveiled a long-term growth plan at its London Capital Markets Day.
The plan targets launching more than five “multi-blockbuster” medicines by 2030.
Novo aims for over DKK 150 billion (?$23 bn) risk-adjusted pipeline sales by 2035.
CagriSema showed 12.4% weight loss versus 9.1% tirzepatide and 21% versus placebo in late-stage trials.
Novo’s shares fell over 70% from their peak, dropping 4-7% after the announcement.

1 / 2